The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2− breast cancer patients-Reference-Cited by-同舟云学术

The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2− breast cancer patients

Published:2013-10-24 Issue:12 Volume:109 Page:2959-2964
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Dubsky P, ,Brase J C,Jakesz R,Rudas M,Singer C F,Greil R,Dietze O,Luisser I,Klug E,Sedivy R,Bachner M,Mayr D,Schmidt M,Gehrmann M C,Petry C,Weber K E,Fisch K,Kronenwett R,Gnant M,Filipits M

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/bjc2013671.pdf

Reference23 articles.

1. Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Alencar VH, Badran A, Bonfill X, Bradbury J, Clarke M, Collins R, Davis SR, Delmestri A, Forbes JF, Haddad P, Hou MF, Inbar M, Khaled H, Kielanowska J, Kwan WH, Mathew BS, Mittra I, Muller B, Nicolucci A, Peralta O, Pernas F, Petruzelka L, Pienkowski T, Radhika R, Rajan B, Rubach MT, Tort S, Urrutia G, Valentini M, Wang Y, Peto R (2012) Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 381: 805–816.

2. Dubsky P, Filipits M, Jakesz R, Rudas M, Singer C, Greil R, Dietze O, Luisser I, Klug E, Sedivy R, Bachner M, Mayr D, Schmidt M, Gehrmann M, Petry C, Weber K, Kronenwett R, Brase J, Gnant M (ABCSG). (2012a) EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2−negative early breast cancer. Ann Oncol 24: 640–647.

3. Dubsky PC, Jakesz R, Mlineritsch B, Postlberger S, Samonigg H, Kwasny W, Tausch C, Stoger H, Haider K, Fitzal F, Singer CF, Stierer M, Sevelda P, Luschin-Ebengreuth G, Taucher S, Rudas M, Bartsch R, Steger GG, Greil R, Filipcic L, Gnant M (2012b) Tamoxifen and anastrozole as a sequencing strategy: a randomized controlled trial in postmenopausal patients with endocrine-responsive early breast cancer from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol 30: 722–728.

4. EBCTCG (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365 (9472): 1687–1717.

5. Esserman LJ, Moore DH, Tsing PJ, Chu PW, Yau C, Ozanne E, Chung RE, Tandon VJ, Park JW, Baehner FL, Kreps S, Tutt AN, Gillett CE, Benz CC (2011) Biologic markers determine both the risk and the timing of recurrence in breast cancer. Breast Cancer Res Treat 129 (2): 607–616.

Cited by 275 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Optimizing transcriptome-based synthetic lethality predictions to improve precision oncology in early-stage breast cancer: BC-SELECT;2024-08-21

2. Enhancing clinical decision support with genomic tools in breast cancer: A Scottish perspective;The Breast;2024-06

3. Impact of Prosigna test on adjuvant treatment decision in lymph node-negative early breast cancer—a prospective national multicentre study (EMIT-1);ESMO Open;2024-06

4. Clinical and molecular predictors of very late recurrence in oestrogen receptor-positive breast cancer patients;Breast Cancer Research and Treatment;2024-05-06

5. Gene Expression Assays to Tailor Adjuvant Endocrine Therapy for HR+/HER2− Breast Cancer;Clinical Cancer Research;2024-04-24